Mechanistically, TLR7/8 agonists were shown to enhance maturation of MDSCs and/or M2 macrophages, promoting their conversion to APCs and M1-like macrophages and resulting in stimulation of tumor-specific T cell responses [97]. Here, TLR7 is linked to neoplasm.